Feb 28, 2017 7:00am EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
Feb 08, 2017 7:00am EST Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Jan 09, 2017 7:00am EST Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
Dec 21, 2016 7:00am EST Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
Dec 16, 2016 7:00am EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
Nov 25, 2016 7:00am EST Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
Nov 16, 2016 7:00am EST American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
Nov 09, 2016 7:00am EST Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
